Lumos Diagnostics Holdings Ltd. LDX
ASX · Australia · Health Technology
AUD 0.10000.00 (0.00%)
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has expanded the live rollout of its FebriDx rapid diagnostic test to 215 US urgent care sites, up from 170, as commercial traction builds across major health-system-owned networks. The number of sites actively evaluating FebriDx has also...
Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has entered the new financial year with a significantly expanded US opportunity for its FebriDx rapid diagnostic test after securing regulatory, reimbursement and distribution milestones during the 12 months to June 30, 2026. Revenue for the...
Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) is moving into the commercial phase of its US FebriDx strategy after securing the regulatory clearance, distribution network and funding needed to pursue the outpatient healthcare market. oppurtunity The US Food and Drug Administration...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.